Sent by e-mail only: XXXXXXXXXXXXXXXXXXX

National Haemoglobinopathy Panel

Women's and Children's Academic Health

Kings College London

Becket House

1 Lambeth Palace Road

London

SE1 7EU

11 September 2023

Dear XXXXXXXXXXXXXXXXXXXXXX

**Re: Final Appraisal Document — Voxelotor for treating haemolytic anaemia caused by sickle cell disorder (SCD) (ID1403)**

I wrote to you on 18 August 2023, following receipt of your appeal letter dated 10 August 2023.

In that letter I explained the requirements for making an appeal, that I could not identify any specific appeal points under the relevant grounds of appeal from your letter of 10 August 2023 and that you had 10 working days to submit any further clarifications and/or evidence for me to consider. I invited you to take that second opportunity to submit specific appeal points under NICE's grounds of appeal in response to this letter.

I note you have provided no response to my letter of 18 August 2023. I therefore remain unable to clarify the basis of your appeal or to provide my initial views on whether your letter presents any arguable point(s) of appeal. Therefore I will not be referring any appeal points from the NHP to the Appeal Panel.

I can however confirm that an appeal will be held to consider valid appeal points raised by other appellants, the process and outcome of which will be available to you on NICE's website here: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10505/documents>

Yours sincerely

XXXXXXXXXXXXXXXX

Dr Mark Chakravarty

Lead Non-Executive Director for Appeals & Vice Chairman

National Institute for Health and Care Excellence